Photo of Kathleen A. McGinley

Kathleen McGinley is a principal and the office litigation manager of the Baltimore, Maryland, office of Jackson Lewis P.C. She is an experienced litigator and represents private and public sector employers in all areas of employment law.

The Maryland Department of Labor is proposing delaying implementation of the Family and Medical Leave Insurance (FAMLI) program. Under the new recommended plan, payroll deductions would begin January 1, 2027 and benefits would become available on January 1, 2028. This proposed change will need to be approved by the General Assembly. In light of the

Employers face a complicated patchwork of state, local and federal laws governing time off for family and medical reasons. The intersection of these often-overlapping laws creates numerous issues including how to handle time off that qualifies under both state paid family medical leave (PFML) laws and the federal Family and Medical Leave Act (FMLA). On

As more employers incorporate wearable technology in the workplace, including those enhanced by artificial intelligence, the Equal Employment Opportunity Commission (EEOC)’s new fact sheet “Wearables in the Workplace: The Use of Wearables and Other Monitoring Technology Under Federal Employment Discrimination Laws,” offers important considerations for employers.  The EEOC explains how employers can navigate

The Maryland Department of Labor recently published proposed regulations to implement the state’s paid family and medical leave insurance program. Although they are not final yet, the proposed regulations provide important information for employers as they prepare for the new mandatory program. Payroll deductions will start July 1, 2025, and benefits will be available beginning

The DOL Wage and Hour Division’s recently issued opinion letter clarifies the scope of permitted uses of Family Medical Leave Act leave. Specifically, it affirms that eligible employees may use FMLA leave for medical interventions provided as part of clinical trials, regardless of whether the treatment is experimental or involves placebos. Highlights from the DOL’s